Elotuzumab


Combined with:

Dexamethasone

Indications and Reactions:

Role Indications Reactions
Secondary
Product Used For Unknown Indication 45.9%
Adverse Event 16.2%
Plasma Cell Myeloma 14.4%
Multiple Myeloma 13.6%
Drug Use For Unknown Indication 7.2%
Premedication 0.6%
Prophylaxis 0.3%
Hypertension 0.3%
Depression 0.2%
Thrombosis Prophylaxis 0.2%
Anaemia 0.2%
Constipation 0.2%
Diarrhoea 0.2%
Nausea 0.2%
Plasma Cell Leukaemia 0.2%
Supplementation Therapy 0.2%
Abdominal Pain Lower 0.1%
Atrial Fibrillation 0.1%
Indigestion 0.1%
Platelet Count Decreased 0.1%
Plasma Cell Myeloma 12.5%
Chest Pain 11.5%
Pneumonia 7.7%
Renal Failure Acute 6.7%
Pleural Mesothelioma 5.8%
Thrombocytopenia 5.8%
Benign Prostatic Hyperplasia 4.8%
Hyponatraemia 4.8%
Pulmonary Embolism 4.8%
Chronic Lymphocytic Leukaemia 3.8%
Febrile Neutropenia 3.8%
Sepsis 3.8%
Urinary Tract Infection 3.8%
Death 2.9%
Hemiparesis 2.9%
Myelodysplastic Syndrome 2.9%
Overdose 2.9%
Renal Failure 2.9%
Respiratory Tract Infection 2.9%
Spinal Compression Fracture 2.9%
Concomitant
Product Used For Unknown Indication 52.2%
Drug Use For Unknown Indication 19.6%
Plasma Cell Myeloma 19.6%
Multiple Myeloma 8.7%
Thrombosis 40.0%
Atrial Fibrillation 20.0%
Hyperglycaemia 20.0%
Neuropathy Peripheral 20.0%

Drug Data